Trial Profile
Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Pregnenolone methyl ether (Primary)
- Indications Depressive disorders
- Focus Therapeutic Use
- Sponsors Mapreg
- 03 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Mar 2025.
- 03 Apr 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Dec 2024.
- 10 Nov 2022 Planned End Date changed from 1 Jun 2021 to 1 Dec 2023.